Michael Ohlmeyer

Dr. Michael Ohlmeyer

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2017 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JSJaya Sangodkar
Jaya Sangodkar
APAbbey Perl
Abbey Perl
RTRita Tohme
Rita Tohme
JKJanna Kiselar
Janna Kiselar
DKDavid B. Kastrinsky
David B. Kastrinsky
GNGoutham Narla
Goutham Narla
Targeted cancer therapies, which act on specific cancer-associated molecular targets, are predominantly inhibitors of oncogenic kinases. While these drugs have achieved some clinical success, the inactivation of kinase signaling via stimulation of endogenous phosphatases has received minimal attention as an alternative targeted approach. Here, we have demonstrated that activation of the tumor suppressor protein phosphatase 2A (PP2A), a negative regulator of multiple oncogenic signaling proteins, is a promising therapeutic approach for the treatment of cancers. Our group previously developed a series of orally bioavailable small molecule activators of PP2A, termed SMAPs. We now report that SMAP treatment inhibited the growth of KRAS-mutant lung cancers in mouse xenografts and transgenic models. Mechanistically, we found that SMAPs act by binding to the PP2A Aα scaffold subunit to drive conformational changes in PP2A. These results show that PP2A can be activated in cancer cells to inhibit proliferation. Our strategy of reactivating endogenous PP2A may be applicable to the treatment of other diseases and represents an advancement toward the development of small molecule activators of tumor suppressor proteins.

1 October 2015 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
DKDavid B. Kastrinsky
David B. Kastrinsky
JSJaya Sangodkar
Jaya Sangodkar
NZNilesh Zaware
Nilesh Zaware
SISudeh Izadmehr
Sudeh Izadmehr
NDNeil S. Dhawan
Neil S. Dhawan
MOMichael Ohlmeyer
Michael Ohlmeyer

21 February 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
RTRita Tohmé
Rita Tohmé
SISudeh Izadmehr
Sudeh Izadmehr
SGSai Gandhe
Sai Gandhe
GTGiancarlo Tabaro
Giancarlo Tabaro
SVSanjay Vallabhaneni
Sanjay Vallabhaneni
GNGoutham Narla
Goutham Narla
Although tyrosine kinase inhibitors (TKIs) have demonstrated significant efficacy in advanced lung adenocarcinoma (LUAD) patients with pathogenic alterations in EGFR, most patients develop acquired resistance to these agents via mechanisms enabling the sustained activation of the PI3K and MAPK oncogenic pathways downstream of EGFR. The tumor suppressor protein phosphatase 2A (PP2A) acts as a negative regulator of these pathways. We hypothesize that activation of PP2A simultaneously inhibits the PI3K and MAPK pathways and represents a promising therapeutic strategy for the treatment of TKI-resistant LUAD. After establishing the efficacy of small molecule activators of PP2A (SMAPs) in a transgenic EGFR L858R model and TKI-sensitive cell lines, we evaluated their therapeutic potential in vitro and in vivo in TKI-resistant models. PP2A activation resulted in apoptosis, significant tumor growth inhibition, and downregulation of PI3K and MAPK pathways. Combination of SMAPs and TKI afatinib resulted in an enhanced effect on the downregulation of the PI3K pathway via degradation of the PP2A endogenous inhibitor CIP2A. An improved effect on tumor growth inhibition was observed in a TKI-resistant xenograft mouse model treated with a combination of both agents. These collective data support the development of PP2A activators for the treatment of TKI-resistant LUAD.

24 February 2020 in Neurotherapeutics
Verified
Journal Article
Closed access
PDF file
HWHui Wei
Hui Wei
HZHui-Liang Zhang
Hui-Liang Zhang
XWXiao-Chuan Wang
Xiao-Chuan Wang
JXJia-Zhao Xie
Jia-Zhao Xie
DADan-Dan An
Dan-Dan An
Rong LiuRong Liu
Rong Liu

13 September 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
FFFabian A. Fischer
Fabian A. Fischer
LMLinda F. M. Mies
Linda F. M. Mies
SNSohaib Nizami
Sohaib Nizami
EPEirini Pantazi
Eirini Pantazi
SDSara Danielli
Sara Danielli
JBJelena S Bezbradica
Jelena S Bezbradica
Significance: The NLRP3 inflammasome is an innate sensor activated by signals released from pathogens or injured tissues. Activation of the NLRP3 inflammasome can be beneficial during infection and vaccination. Nonetheless, when NLRP3 activity is uncontrolled and chronic it becomes detrimental and contributes to inflammation-driven pathology in several diseases. Licensing mechanisms must exist that prevent unwanted NLRP3 inflammasome responses. Here, we characterize one such mechanism. We describe that TBK1 and IKKε, two closely related kinases activated upon TLR signaling, act as a novel OFF switch for the NLRP3 pathway. Using pharmacological and genetic approaches, we show that TBK1 and IKKε together limit the responses downstream of the NLRP3 inflammasome activation and work against the PP2A phosphatase ON switch to balance NLRP3 activity.

13 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
LBLaura Bownes
Laura Bownes
RMRaoud Marayati
Raoud Marayati
CQColin Quinn
Colin Quinn
ABAndee M. Beierle
Andee M. Beierle
SHSara C. Hutchins
Sara C. Hutchins
EBElizabeth Beierle
Elizabeth Beierle
Background: Protein phosphatase 2A (PP2A) functions as an inhibitor of cancer cell proliferation, and its tumor suppressor function is attenuated in many cancers. Previous studies utilized FTY720, an immunomodulating compound known to activate PP2A, and demonstrated a decrease in the malignant phenotype in neuroblastoma. We wished to investigate the effects of two novel PP2A activators, ATUX-792 (792) and DBK-1154 (1154). Methods: Long-term passage neuroblastoma cell lines and human neuroblastoma patient-derived xenograft (PDX) cells were used. Cells were treated with 792 or 1154, and viability, proliferation, and motility were examined. The effect on tumor growth was investigated using a murine flank tumor model. Results: Treatment with 792 or 1154 resulted in PP2A activation, decreased cell survival, proliferation, and motility in neuroblastoma cells. Immunoblotting revealed a decrease in MYCN protein expression with increasing concentrations of 792 and 1154. Treatment with 792 led to tumor necrosis and decreased tumor growth in vivo. Conclusions: PP2A activation with 792 or 1154 decreased survival, proliferation, and motility of neuroblastoma in vitro and tumor growth in vivo. Both compounds resulted in decreased expression of the oncogenic protein MYCN. These findings indicate a potential therapeutic role for these novel PP2A activators in neuroblastoma.